Evolus, Inc. (NASDAQ:EOLS) Given Consensus Rating of "Moderate Buy" by Analysts

Key Points

• Evolus, Inc. has received an average rating of "Moderate Buy" from five research firms, with one hold and four buy recommendations.
• The average 1-year price objective for Evolus stock among analysts is $21.25, although recent ratings have seen price objectives adjusted downward.
• Insider transactions showed a significant purchase by Director Albert G. White III, who acquired 20,000 shares, indicating confidence in the company's prospects.

Evolus, Inc. (NASDAQ:EOLS - Get Free Report) has been given an average rating of "Moderate Buy" by the five brokerages that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month target price among analysts that have covered the stock in the last year is $21.25.

Several brokerages have issued reports on EOLS. Needham & Company LLC reaffirmed a "hold" rating and issued a $22.00 price target on shares of Evolus in a report on Wednesday, August 6th. HC Wainwright cut their price objective on shares of Evolus from $27.00 to $20.00 and set a "buy" rating for the company in a research report on Wednesday, August 6th. BTIG Research cut their price objective on shares of Evolus from $21.00 to $18.00 and set a "buy" rating for the company in a research report on Wednesday, August 6th. Finally, Wall Street Zen lowered shares of Evolus from a "hold" rating to a "sell" rating in a research report on Saturday.

Insider Buying and Selling at Evolus

In other news, insider David Moatazedi sold 16,582 shares of the company's stock in a transaction on Monday, June 16th. The shares were sold at an average price of $9.89, for a total value of $163,995.98. Following the completion of the transaction, the insider directly owned 364,927 shares in the company, valued at approximately $3,609,128.03. This represents a 4.35% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Albert G. White III bought 20,000 shares of the firm's stock in a transaction dated Monday, June 9th. The stock was purchased at an average price of $9.45 per share, with a total value of $189,000.00. Following the completion of the purchase, the director directly owned 50,378 shares of the company's stock, valued at approximately $476,072.10. This trade represents a 65.84% increase in their position. The disclosure for this purchase can be found here. 6.10% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. AlphaQuest LLC bought a new stake in Evolus in the 1st quarter valued at about $39,000. State of Wyoming increased its stake in Evolus by 988.1% during the 1st quarter. State of Wyoming now owns 3,754 shares of the company's stock valued at $45,000 after buying an additional 3,409 shares during the period. IFP Advisors Inc increased its stake in Evolus by 99.0% during the 1st quarter. IFP Advisors Inc now owns 9,427 shares of the company's stock valued at $113,000 after buying an additional 4,691 shares during the period. KLP Kapitalforvaltning AS purchased a new position in Evolus during the fourth quarter valued at approximately $106,000. Finally, Rafferty Asset Management LLC purchased a new position in Evolus during the fourth quarter valued at approximately $115,000. 90.69% of the stock is currently owned by institutional investors.

Evolus Price Performance

Shares of NASDAQ EOLS traded up $0.63 on Friday, hitting $6.40. The company's stock had a trading volume of 1,827,552 shares, compared to its average volume of 1,102,128. Evolus has a 12-month low of $5.71 and a 12-month high of $17.82. The company has a market capitalization of $413.95 million, a price-to-earnings ratio of -6.53 and a beta of 1.12. The company has a debt-to-equity ratio of 22.00, a current ratio of 2.27 and a quick ratio of 1.86. The stock has a 50 day moving average of $9.16 and a 200-day moving average of $11.04.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.